Pneumonia in the face of COVID-19

EditorialPneumonia in the face of COVID-19Martin Witzenrath and Wolfgang M. KueblerMartin WitzenrathDepartment of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin, Humboldt Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyDivision of Pulmonary Inflammation, Charité-Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin, Humboldt Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyGerman Center for Lung Research (DZL), Partner site Berlin, Germany and Wolfgang M. KueblerInstitute of Physiology, Charité-Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin, Humboldt Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyGerman Center for Lung Research (DZL), Partner site Berlin, GermanyGerman Center for Cardiovascular Research (DZHK), Partner site Berlin, GermanyKeenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Ontario, CanadaDepartments of Physiology and Surgery, University of Toronto, Toronto, Ontario, CanadaPublished Online:04 Nov 2020https://doi.org/10.1152/ajplung.00447.2020This is the final version - click for previous versionMoreFiguresReferencesRelatedInformationSectionsDISCLOSURESAUTHOR CONTRIBUTIONSAUTHOR NOTESPDF (100 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookXLinkedInWeChat In this issue of the American Journal of Physiology-Lung Cellular and Molecular Physiology the Global Coalition Against Pneumonia draws attention to World Pneumonia Day on November 12 in two accompanying editorials (12, 28). This annual event recognizes the global burden of what William Osler once called not only the most widespread and fatal of all acute infectious diseases, but the "captain of the men of death" (26). While this statement has probably been true since the beginnings of humankind, the threat of pneumonia tends to receive specific attention during global outbreaks such as the ongoing coronavirus disease 2019 (COVID-19) pandemic or the Spanish flu 1918–1920. However, it is important to recognize that even before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pneumonia was already the most frequent cause of death among all infectious diseases in both adults and infants (30). Unavailability of vaccines and antimicrobials for the prevention and treatment of pneumonia contributes to high morbidity and mortality in developing countries. Further, antimicrobial drug resistance, particularly in pathogens causing pneumonia (27), is a growing challenge worldwide. As a result of new resistance mechanisms and their rapid distribution, multidrug-resistant bacteria are spreading globally. Recent studies estimate that within the United States and the European Union, ∼23,000 and 33,000 patients, respectively, die each year from an infection with a resistant pathogen (8, 9). As far more people are infected, the socio-economic impact of multidrug resistance is enormous and growing steadily. While novel antibiotics are thus in dire need, respective research and development programs in infectious diseases have been minimized by the pharmaceutical industry in the past years (23). Importantly, however, in most fatal cases pneumonia is caused by bacteria without antimicrobial drug resistance and despite patients being treated with appropriate antibiotics. In these cases, killing of bacteria is not sufficient to prevent lung injury as a result from the abundance of pathogen-associated molecular patterns (PAMPs) and exotoxins, the infiltration and activation of inflammatory cells, the release of cytokines, lipid mediators, and extracellular traps, and the activation of complement and coagulation cascades. The resulting disruption of the alveolo-capillary barrier causes extravasation of proteinaceous fluid into the alveolar space, impairing lung mechanics and gas exchange and culminating in the clinical picture of the acute respiratory distress syndrome (ARDS) with mortality rates of 35–46% (2). Simultaneously, barrier failure promotes the systemic dissemination of infection and inflammation, the development of sepsis, and progressive multiorgan involvement. Even in the absence of overt ARDS, pneumonia may result in distinct acute or chronic systemic organ injury, evident, e.g., as direct cardiac damage by bacterial invasion into the myocardium and formation of microscopic lesions finally leading to cardiac scarring (25) or as atherosclerotic plaque formation in systemic arteries that can be causally linked to pulmonary inflammation (4). Notably, this sequence of events also adequately describes disease progression in the current COVID-19 pandemic. Following initial infection of the airways with SARS-CoV-2, an inflammatory response emerges that—if uncontrolled—can disseminate throughout the body and cause systemic organ involvement. While occasional reports have highlighted the detection of viral RNA or virus-like particles in systemic organs such as the kidney or the gastrointestinal tract (5, 24), it is important to note that viral infection of and replication in systemic organs has so far—to our knowledge—not been demonstrated. The presence of viral RNA or particles in systemic organs may in fact be attributable to infiltration of macrophages with a positive SARS-CoV-2 signal from the lung, e.g., into the heart, which however does not implicate that these viral particles may be infectious (18). As such, systemic dissemination of COVID-19 and acute or chronic injury and functional impairment of the heart, kidney, or central nervous system are likely the result of an out-of-proportion immune response that involves the parallel activation of related cascades such as the complement and coagulation system. Consistently, biomarker studies by us and others have identified cytokines such as interleukin-6 or complement factors as circulating biomarkers in COVID-19 with plasma concentrations increasing as a function of disease severity (15, 19). At present, COVID-19 is more deadly than influenza, and in contrast to the latter no SARS-CoV-2 vaccine has yet been proven to be both efficacious and safe. But even when a vaccine would become broadly available, this would likely not be the end of the present pandemic—because not all people would get vaccinated, because vaccination may not be effective in a considerable percentage, and because immunity may only be temporary. Notably, vaccines against influenza virus or Streptococcus pneumoniae have been available for many years, yet people still die from influenza or pneumococcal pneumonia. Hence, the problem of pneumonia will not be solved by antimicrobial strategies and vaccines alone. It is fair to assume that the same holds true for COVID-19. As such, it becomes ever more important to understand the "physiological" basis of pneumonia and to utilize this knowledge for the development of targeted adjunctive therapies to fight disease manifestation and dissemination. Besides aiming to control excessive inflammation and coagulation such adjunctive therapies may and should comprise strategies to stabilize the alveolo-capillary barrier and thus, not only to prevent permeability-type lung edema and subsequent hypoxemia, but also to limit the invasion of bacteria and the development of sepsis. Barrier protection may in principle follow one of three general strategies: First, barrier-disruptive mediators may be antagonized by, e.g., neutralizing antibodies or receptor blockers. While this approach seems intuitive, it has proven not effective in clinical trials targeting specific cytokines or lipid mediators, presumably because barrier failure is not caused by a single disruptive agent but a combination of endogenous (and exogenous) factors acting on the alveolar epithelium and capillary endothelium. To overcome this limitation, a second strategy aims to target common cellular pathways of barrier disruption. This approach has been effectively realized, e.g., by antagonists against the multimodal cation channel transient receptor potential vanilloid 4 (TRPV4). Activation of TRPV4 seems to constitute a critical event in alveolo-capillary barrier failure in response to a range of different infectious or injurious stimuli including acid or chlorine gas induced injury, ventilator-induced lung injury, pneumococcal pneumonia, or cardiogenic lung edema (1, 20, 21, 32, 33). While an abundance of preclinical data highlight the potential of this approach, clinical studies still have to prove the validity of this concept in patients with pneumonia, COVID-19, or ARDS (17). Third, a group of endogenous mediators or derivatives have been identified that seem to exert barrier-protective effects largely independent of the underlying disease. These include but are not limited to sphingosine-1-phosphate, adrenomedullin, angiotensin-(1-7), or angiopoietin-1 (13, 14, 22, 29). Accordingly, several clinical trials presently aim to exploit this strategy for the fight against COVID-19 (NCT04375124, NCT04417036). Importantly, barrier stabilization may no longer be efficient once ARDS has occurred. Hence, it will be critical to identify patients at risk for barrier failure at an early disease stage. Of late, patient stratification by subphenotyping using latent class analyses has provided promising results in ARDS patients in that it allowed to differentiate patients who may or may not profit from specific interventions including ventilatory (6), fluid management (11), or pharmacological strategies (7). Similarly, the relatively slow development of COVID-19 from initial SARS-CoV-2 infection to overt ARDS has fueled the search for predictive biomarkers of disease progression and severity (10, 31). Yet at present, C-reactive protein and procalcitonin are still the most widely used biomarkers in community-acquired pneumonia, even though their shortcomings are well recognized (16). As such, better and innovative strategies for the stratification of pneumonia patients remain in dire need. Notably, such strategies should not focus primarily on the pathogen but on the individual host and its response to infection. Heterogeneity in genetic predisposition, comorbidities, comedication, infectious pathogen, and the ensuing host response, however, make the discovery of a single common biomarker rather unlikely. As such, systems-medicine approaches based on –omics data (including genomics, epigenomics, transcriptomics, proteomics, lipidomics, glycomics, metabolomics, and microbiomics) may help identify composite signatures that better reflect this complexity and assist not only in patient stratification, but also in guided therapy and monitoring of treatment responses. In parallel, appropriate preclinical models including small and large animal models, human tissue, and human organoids are required to mimic all aspects of the disease, allowing for rigorous testing of novel treatment strategies in multidimensional systems (3). Up to now, therapeutic concepts for the treatment of pneumonia have been largely driven by a pathogen-centric view based on the individual antibiotic spectrum. In contrast, the role of the host has been largely underestimated. The relevance of this role has become strikingly evident in the present COVID-19 pandemic where the same virus causes a wide range of disease severities that spans from asymptomatic infections to severe ARDS and fatal multiorgan dysfunction. The development of a more host-centric view, however, requires better mechanistic insights into pneumonia in terms of host defense, injury, and repair versus aggravation. In brief, we need to apply physiology to get a better understanding of pathology that may, hopefully, fuel novel therapies.DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONS M.W. and W.M.K. drafted manuscript; edited and revised manuscript; and approved final version of manuscript.AUTHOR NOTESCorrespondence: W. M. Kuebler (wolfgang.kuebler@charite.de). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationREFERENCES1. Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, Yu Z, Sui A, Cheung M, Leishman E, Eidam HS, Ye G, Willette RN, Thorneloe KS, Bradshaw HB, Matalon S, Jordt SE. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 307: L158–L172, 2014. doi:10.1152/ajplung.00065.2014. Link | Web of Science | Google Scholar2. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315: 788–800, 2016. doi:10.1001/jama.2016.0291. Crossref | PubMed | Web of Science | Google Scholar3. Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, Maes T, Shi W, Stampfli M, Uhlig S, White E, Witzenrath M, Bellaye PS, Crestani B, Eickelberg O, Fehrenbach H, Guenther A, Jenkins G, Joos G, Magnan A, Maitre B, Maus UA, Reinhold P, Vernooy JHJ, Richeldi L, Kolb M. Optimising experimental research in respiratory diseases: an ERS statement. Eur Respir J 51: 1702133, 2018. doi:10.1183/13993003.02133-2017. Crossref | PubMed | Web of Science | Google Scholar4. Brack MC, Lienau J, Kuebler WM, Witzenrath M. Cardiovascular sequelae of pneumonia. Curr Opin Pulm Med 25: 257–262, 2019. doi:10.1097/MCP.0000000000000584. Crossref | PubMed | Web of Science | Google Scholar5. Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, Najafian B, Deutsch G, Lacy JM, Williams T, Yarid N, Marshall DA. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet 396: 320–332, 2020. doi:10.1016/S0140-6736(20)31305-2. Crossref | PubMed | Web of Science | Google Scholar6. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2: 611–620, 2014. doi:10.1016/S2213-2600(14)70097-9. Crossref | PubMed | Web of Science | Google Scholar7. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF, Johnston AJ, Paikray A, Yates C, Polgarova P, Price E, McInerney A, Zamoscik K, Dempsey G, Seasman C, Gilfeather L, Hemmings N, O'Kane S, Johnston P, Pokorny L, Nutt C, O'Neill O, Prashast P, Smalley C, Jacob R, O'Rourke J, Sultan SF, Schilling C, Perkins GD, Melody T, Couper K, Daniels R, Gao F, Hull J, Gould T, Thomas M, Sweet K, Breen D, Neau E, Peel WJ, Jardine C, Jefferson P, Wright SE, Harris K, Thomas M, Hierons S, Laffey J, McInerney V, Camporota L, Lei K, Kaul S, Chibvuri M, Gratrix A, Bennett R, Martinson V, Sleight L, Smith N, Hopkins PA, Hadfield D, Casboult S, Wade-Smith F, Dawson J, Mellis C, Harris C, Parsons G, Helyar S, Bodenham AR, Elliot S, Beardow Z, Birch S, Marsh B, Martin T, Dhrampal A, Rosbergen M, Webb S, Bottrill F, Reschreiter H, Barcraft-Barnes H, Camsooksai J, Johnston A, Clarkson A, Bentley C, Cooper L, Qui Y, Mitchell N, Carrera R, Whitehouse A, Danbury CM, Jacques N, Brown A, Rogerson D, Morris C, Walsh T, Gillies M, Price G, Kefala K, Young N, Hope D, McCulloch C, Antonelli J, Ramsay P, Everingham K, Boardman L, Dawson H, Pollock F, Thompson J, Welters ID, Poole L, Hampshire P, Hall A, Williams K, Walker A, Youds L, Hendry S, Waugh V, Patrick-Heselton J, Shaw D, Chaudry I, Baldwin J, Drage S, Ortiz-Ruiz de Gordoa L, McAuley D, Bannon L, Quinn V, McNamee L, White G, Cecconi M, Mellinghoff J, Ryan D, Nichol A, Agarwal B, Meale P, James S, Dhadwal K, Martin D, Walecka A, Ward S, Trinder J, Hagan S, Montgomery J, Leonard C, Lemon E, Trinick T, Buddhavarapu M, Ward G, Bassford C, Davidson A, McGuigan K, Benchiheub A, Hickey N, Binning A, Henderson S, Wood JA, Burtenshaw AJ, Kelly D, Martin T, Thrush J, Wollaston J, Graystone S, Nicol G, Sellors G; Irish Critical Care Trials Group. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 6: 691–698, 2018. doi:10.1016/S2213-2600(18)30177-2. Crossref | PubMed | Web of Science | Google Scholar8. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL, Strauss R, Mertens K, Struyf T, Catry B, Latour K, Ivanov IN, Dobreva EG, Tambic Andraševic A, Soprek S, Budimir A, Paphitou N, Žemlicková H, Schytte Olsen S, Wolff Sönksen U, Märtin P, Ivanova M, Lyytikäinen O, Jalava J, Coignard B, Eckmanns T, Abu Sin M, Haller S, Daikos GL, Gikas A, Tsiodras S, Kontopidou F, Tóth Á, Hajdu Á, Guólaugsson Ó, Kristinsson KG, Murchan S, Burns K, Pezzotti P, Gagliotti C, Dumpis U, Liuimiene A, Perrin M, Borg MA, de Greeff SC, Monen JCM, Koek MBG, Elstrøm P, Zabicka D, Deptula A, Hryniewicz W, Caniça M, Nogueira PA, V, E, S, M, J, I, A, B, A, M, H, Larsson S, A, Hopkins of Group. and caused by infections with bacteria in the and the European in a Lancet 2019. Crossref | PubMed | Web of Science | Google for and S, H, S, B, Y, T, D, A, T, H, van O, A, P, J, E, S, M, A, A, J, D, K, C, M, S, M, inflammatory COVID-19 severity and death 2020. Delucchi K, Ware LB, Liu Thompson BT, Calfee ARDS Network. ARDS Network. Acute respiratory distress syndrome subphenotypes to fluid management strategy in Am J Respir Care Med Am J Respir Care Med Crossref | PubMed | Web of Science | Google World Pneumonia Day during a global pneumonia 12 November 2020. Am J Physiol Lung Cell Mol In Link | Web of Science | Google B, K, C, A, J, M, N, L, Mitchell S, S, N, Witzenrath and and role of angiopoietin-1 and in pneumonia. Am J Respir Care Med 2018. Crossref | PubMed | Web of Science | Google B, C, R, K, W, L, Kuebler WM, K, E, A, F, B, Mitchell W, B, D, F, M, N, S, N, Witzenrath Group. inflammation and contributes to acute lung injury in pneumococcal pneumonia the receptor Care Med 2018. Crossref | PubMed | Web of Science | Google T, V, C, M, M, of and the need for in COVID-19. J 2020. Crossref | PubMed | Web of Science | Google M, in J Mol 20, 2019. Crossref | PubMed | Web of Science | Google Kuebler WM, Jordt SE, of lung edema as a in inhibition of TRPV4 a promising and Am J Physiol Lung Cell Mol Physiol 2020. Link | Web of Science | Google D, A, H, G, C, K, K, P, F, S, K, of cardiac infection with SARS-CoV-2 in COVID-19 JAMA In Crossref | PubMed | Web of Science | Google V, D, L, White M, A, K, AS, M, D, C, F, A, C, M, S, A, C, A, C, C, KS, Kuebler WM, M, C, N, Witzenrath M, F, and M. clinical of COVID-19 infection. Cell 2020. Crossref | PubMed | Web of Science | Google L, L, U, van M, W, Kuebler receptor potential vanilloid 4 and are critical mediators of lung injury in in Crossref | PubMed | Web of Science | Google L, Kuebler and 2020. Crossref | PubMed | Web of Science | Google H, Lienau J, N, Witzenrath M. strategies in antibiotics. Eur Respir Crossref | PubMed | Web of Science | Google European of and Infectious of development of new antimicrobial a potential threat to Lancet Crossref | PubMed | Web of Science | Google M, L, S, A, N, Liu S, F, S, S, AS, C, O, M, D, T, S, K, M, and of J Med 2020. Crossref | PubMed | Web of Science | Google A, N, A, S, O, LD, CS, Witzenrath M, N, pneumococcal pneumonia causes acute cardiac and subsequent cardiac Am J Respir Care Med Crossref | PubMed | Web of Science | Google the new "captain of the men of its increasing and the of for its JAMA | Google M, I, of and in PubMed | Google E, R, S, from pneumonia. Am J Physiol Lung Cell Mol In | Web of Science | Google T, Kuebler the role of the system and its therapeutic potential in COVID-19. Am J Physiol Lung Cell Mol Physiol 2020. Link | Web of Science | Google World Y, C, J, J, J, F, F, G, Y, L, L, M, M, H, W, R, D, Xu Z, H, M, Z, Gao C, Liu L, and Liu and are with disease severity and the progression of COVID-19. J 2020. Crossref | PubMed | Web of Science | Google J, J, N, L, J, W, S, H, AR, Kuebler lung edema a of transient receptor potential vanilloid Crossref | PubMed | Web of Science | Google J, L, C, A, N, K, L, L, G, Witzenrath M, A, L, H, O, A, K, I, H, Kuebler of transient receptor potential vanilloid 4 in activation and acute lung injury. Am J Respir Cell Mol 2016. Crossref | PubMed | Web of Science | Google Pneumonia Day during a global pneumonia 12 November Nov Journal of Physiology-Lung Cellular and Molecular from pneumonia Nov Journal of Physiology-Lung Cellular and Molecular in November and pneumonia, and chronic pulmonary disease in focus Nov Journal of Physiology-Lung Cellular and Molecular for | as an novel biomarker in SARS-CoV-2 | World Journal of of to COVID-19 in | and Infectious of | 21, in November and pneumonia, and chronic pulmonary disease in and November | American Journal of Physiology-Lung Cellular and Molecular Physiology, from this issue the American 4 November in November drug more by on citations Recent this has been at a has been by the of the a it or the and a in which the was more by on in the year of the on the the on the American Journal of Physiology - Lung Cellular and Molecular Physiology, infection and a clinical and American Journal of Physiology - Lung Cellular and Molecular Physiology, of a of in severe coronavirus lung American Journal of Physiology - Lung Cellular and Molecular Physiology, Journal of Physiology - Lung Cellular and Molecular Physiology, and the to the on in of Medicine, Science of Medicine, of injury with the COVID-19 case J Journal of Medicine, SARS-CoV-2 in and Journal of Medicine, acute lung injury in by formation of Science of Medicine, for and COVID-19 statement Journal of Medicine, by

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.